April 15 (Reuters) - Organovo Holdings said on Monday its experimental drug to treat a type of fatty liver disease helped significantly reduce liver fat in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +0.97% | +5.47% | -6.31% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.31% | 11.73M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo's fatty liver disease drug meets main goal in mid-stage study